Long‐Term Outcomes of Neoadjuvant Therapy Versus Upfront Surgery for Resectable Pancreatic Ductal Adenocarcinoma
Cancer Medicine · 2024
DOI: 10.1002/cam4.70363 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Cancer Medicine, 2024. Verfasst von Kyung In Shin und 14 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea. Hauptthemen laut MEDLINE: Neoadjuvant Therapy, Carcinoma, Pancreatic Ductal, Pancreatic Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Yonsei University College of Medicine.
Abstract (Originalsprache)
Introduction
This study aimed to compare the long‐term effects of neoadjuvant therapy and upfront surgery on overall survival (OS) and progression‐free survival (PFS) in patients with resectable pancreatic ductal adenocarcinoma (PDAC).
Methods
We retrospectively analyzed 202 patients, including 167 who had upfront surgery and 35 who received neoadjuvant therapy followed by surgery. Surgical outcomes and survival rates were compared using propensity score matching to minimize selection bias.
Results
Neoadjuvant therapy showed significantly longer 75% OS (72.7 months vs. 28.3 months, p = 0.032) and PFS (29.6 months vs. 13.2 months, p < 0.001) compared to upfront surgery. Additionally, neoadjuvant therapy demonstrated significant improvements in surgical outcomes, including higher R0 resection rates (74.3% vs. 49.5%, p = 0.034), reduced tumor size (22.0 mm vs. 28.0 mm, p = 0.001), and decreased lymphovascular invasion (20.0% vs. 52.4%, p = 0.001).
Conclusion
Our study demonstrates the potential benefits of neoadjuvant therapy for resectable PDAC. The improved survival rates, delayed disease progression, and enhanced surgical outcomes underscore the potential of neoadjuvant therapy in addressing this aggressive disease. Despite limitations such as the retrospective design and small sample size, these findings support the effectiveness of neoadjuvant therapy in improving treatment outcomes for PDAC patients in real‐world settings. Further prospective studies are required to validate these results.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Gastroenterology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
- Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, Korea.
- Department of Hepatobiliary and Pancreatic Surgery, Yonsei University College of Medicine, Seoul, Korea.
- Department of Radiology, Research Institute of Radiological Science, Yonsei University College of Medicine, Seoul, Korea.
ORCID-Profile: Kyung In Shin
Förderung
- Yonsei University College of Medicine
Zitieren
APA
Shin, K. I., Yoon, M. S., Kim, J. H., Jang, W. J., Leem, G., Jo, J. H., Chung, M. J., Park, J. Y., Park, S. W., Hwang, H. K., Kang, C. M., Kim, S. S., Park, M. S., Lee, H. S., & Bang, S. (2024). Long‐Term Outcomes of Neoadjuvant Therapy Versus Upfront Surgery for Resectable Pancreatic Ductal Adenocarcinoma. Cancer Medicine. https://doi.org/10.1002/cam4.70363
Vancouver
Shin KI, Yoon MS, Kim JH, Jang WJ, Leem G, Jo JH, et al. Long‐Term Outcomes of Neoadjuvant Therapy Versus Upfront Surgery for Resectable Pancreatic Ductal Adenocarcinoma. Cancer Medicine. 2024. doi:10.1002/cam4.70363
BibTeX
@article{Shin2024,
author = {Shin, Kyung In and Yoon, Min Sung and Kim, Jee Hoon and Jang, Won Joon and Leem, Galam and Jo, Jung Hyun and Chung, Moon Jae and Park, Jeong Youp and Park, Seung Woo and Hwang, Ho Kyoung and Kang, Chang Moo and Kim, Seung-Seob and Park, Mi-Suk and Lee, Hee Seung and Bang, Seungmin},
title = {Long‐Term Outcomes of Neoadjuvant Therapy Versus Upfront Surgery for Resectable Pancreatic Ductal Adenocarcinoma},
journal = {Cancer Medicine},
year = {2024},
doi = {10.1002/cam4.70363}
}
EUVIMED